RECEIVED
CENTRAL FAX CENTER
MAY 18 2005

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	17

Application Number	10/787,367
Filing Date	February 26, 2004
First Named Inventor	Michael GRAUPE et al.
Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 US CNT

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please identify below):
  1. Form 1449
  2. IDS Fee sheet

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature	Joseph D. Rossi		
Printed name	Joseph ROSSI		
Date	May 18, 2005	Reg. No.	47038

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 17)

Signature			
Typed or printed name	Paul Irvine	Date	May 18, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRAUPE, et al.

Examiner: Coppins, Janet

Art Unit: 1626

Application No.: **10/787,367**

Filed: **February 26, 2004**

Title: **NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS**

Certificate of Mailing or Transmission
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.
Date of Deposit May 18, 2005
Printed Name of Person Signing Certificate Paul Irvine
Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of $180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

Joseph D. Rossi, Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0143 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
GRAUPE, et al.

Application No.: **10/787,367**

Filed: **February 26, 2004**

Title: **NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS**

Examiner: Coppins, Janet

Art Unit: 1626

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

May 18, 2005
Date of Transmission

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982.**

05/19/2005 JBALINAN 00000043 181982 10787367

01 FC:1806 180.00 DA

☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed on pages 1 –13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case:
U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and
U.S. Patent Application Nos. 10/035,783, 10/478,632, 10/719,080, 10/418,183 and 10/294,526.

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement. However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,

Joseph O. Rossi

Joseph Rossi, Reg. No. 47,038
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. USAV2001/0143 US CNT

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4,927,809		STUBER, et al.	05-22-1990	
		5,424,325		ANDO, et al.	06-13-1995	
		5,486,629		ZIMMERMAN, et al.	01-23-1996	
		5,498,616		MALLANO, et al .	03-12-1996	
		5,847,135		BEMIS, et al.	12-08-1998	
		5,852,007		CHATTERJEE, et al.	12-22-1998	
		5,874,424		BATCHELOR, et al.	02-23-1999	
		5,998,390		RAMAMURTHY, et al.	12-07-1999	
		6,004,933		SPRUCE, et al.	12-21-1999	
		6,022,861		SCARBOROUGH, et al.	02-08-2000	
		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	
		6,455,502		BRYANT, et al.	09-24-2002	
		6,476,026		BRYANT, et al.	11-05-2002	
		6,492,362		GRAUPE, et al.	12-10-2002	
		6,506,733		BUYSSE	01-14-2003	
		6,576,630		LINK, et al.	06-10-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		EP	EP 0272671		KRANTZ, et al.	06-29-1988		
		EP	EP 0291234		EDWARDS, et al.	11-17-1988		
		EP	EP 0355572		PAQUES, et al.	02-28-1990		
		EP	EP 0376012		ALBRIGHT, et al.	07-04-1990		
		EP	EP 0419683		HARA, et al.	04-03-1991		
		EP	EP 0536399		OKUBO, et al.	04-01-1993		
		EP	EP 0652009		DOVEY, et al.	10-05-1995		
		EP	EP 0754454		KOBAYASHI, et al.	01-22-1997		
		JP	JP 06192199		RYOICHI, et al.	07-12-1994		
		JP	JP 42009133		IRIKURA, et al.	05-06-1967		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-99)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		10/035,783		GRAUPE, et al.	12-24-2001	
		10/294,526		LI, et al.	11-14-2002	
		US02/17922		GRAUPE, et al.	11-24-2003	
		10/719,080		GRAUPE, et al.	11-21-2003	
		10/418,183		LI, et al.	10-23-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		JP	JP 63303868		YOSHIDA, et al.	12-08-1988		
		WO	WO 00/48992		TUCKER, et al.	08-24-2000		
		WO	WO 00/49007		TUCKER, et al.	08-24-2000		
		WO	WO 00/49008		TUCKER, et al.	08-24-2000		
		WO	WO 00/51998		CYWIN, et al.	09-08-2000		
		WO	WO 00/59881		SINGH, et al.	10-12-2000		
		WO	WO 00/69855		QUIBELL, et al.	11-23-2000		
		WO	WO 01/09110		BEKKALI, et al.	02-08-2001		
		WO	WO 01/19796		GRAUPE, et al.	03-22-2001		
		WO	WO 01/19808		GRAUPE	03-22-2001		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 13

Complete If Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO	WO 01/19816		EMMANUEL, et al.	03-22-2001		
		WO	WO 01/30772		TUCKER, et al.	05-03-2001		
		WO	WO 01/55125		BOZSING, et al.	08-02-2001		
		WO	WO 01/58886		MISSBACH, M	08-16-2001		
		WO	WO 95/13069		MORRIELLO, et al.	05-16-1995		
		WO	WO 95/15309		JENKINS, et al.	06-08-1995		
		WO	WO 95/24382		HALLINAN, et al.	09-14-1995		
		WO	WO 96/21655		PEET, et al.	07-18-1996		
		WO	WO 96/30353		PALMER, et al	10-03-1996		
		WO	WO 96/40647		ZIMMERMAN, et al.	12-19-1996		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO	WO 96/40744		MARLOWE, et al.	12-19-1996		
		WO	WO 96/41638		DOLLE, et al.	12-27-1996		
		WO	WO 97/03679		MALLANO, et al.	02-06-1997		
		WO	WO 98/01133		AIBE, et al.	01-15-1998		
		WO	WO 98/01428		DOMINGUEZ, et al.	01-15-1998		
		WO	WO 98/05336		MARQUIS, et al.	02-12-1998		
		WO	WO 98/08802		YAMASHITA, et al.	03-05-1998		
		WO	WO 98/08867		SHIONOGI, et al.	03-05-1998		
		WO	WO 98/21188		PRESTON, et al.	05-22-1998		
		WO	WO 98/23588		FLOYD, C.	06-04-1998		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1628
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		WO	WO 98/49190		SPRUCE, et al.	11-05-1998		
		WO	WO 99/24460		ALTMANN, et al.	05-20-1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/089 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ADAMS, et al., Potent and Selective Inhibitors of the Proteasom: Dipeptidyl Boronic Acids, Bioogaric & Medicinal Chemistry Letters, 8: 333-338 (1998).	
		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peplidase IV, Bioorganic & Med. Chem. Letters, B,Oxford, 6(22):2745-2748 (1996).	
		BERGEMAN, et al., Studies on the reactivity of .alpha.-cyano.alpha-isocyano alkanoates. Versitile synthons for the assembly of imidazoles, Helv.Chim. ACTA, 82(6):909-918 (1999).	
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cysteinyl , Bioorg. Med. Chem. Lett. vol. 8, pp. 993-998, 1998	
		BROMME, et al., Potent Inactivation of Cathepsins S and L , Biol. Chem. Hoppe–Seyler. vol. 376, No. 5, pp. 343-347, 1994.	
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p: 2663-2666 (1998).	
		COHEN, et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-36 (1999).	
		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Bio.chemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).	
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1654-1663 (1992).	
		EVOLI, et al., abstract only, Drugs, 1996, 52(5), 662-70	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain:nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council. Ottawa, 69(8):1288-1297 (1991).	
		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys, Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and)achalasia) methyl ketones as inhibitors of the enzyme, Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett, 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha.-(acylamino) nitrites and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-93.	
		KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent , Biochemistry. vol. 30, pp. 4678-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	
		LI, et al., Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archives of Biochem. and Biophh., 323(1)148-154 (1995).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		LIPSHUTZ, et al., Chiral induction in orginally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, Isr, J. Chem. 27(1):49-55 (1986), abstract.	
		LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acylamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, . Am. Chem. Soc., 105(26):7703-7713 (1983).	
		LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).	
		MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, Chemical Abstracts, 7:4 581-588 (1999).	
		MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 134(1):105-110 (1997).	
		MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives.sup.1, J. Med. Chem., 29: 333-341 (1986).	
		MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur praparativen herstellung. poly (dipeptamidinium) salts: definition and methods of preperation, Helvitica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1986).	
		NIPPON, K., Patent Abstracts of Japan, Publication No. 63301868, 013(137)(1988), abstract.	
		NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, Tetrahedron, 46(24):8627-8290 (1990).	
		OGILVIE, et al., Peptidomimetic Inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		PICKEN, et al., Inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of calpain and cathepsin B , Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis , BMJ, 321: 19-26 (2000).	
		RIESE, et al., Essential Role for Cathesin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 357-366 (Apr. 1996).	
		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofuctionallzed enamines and monofuntionalized methyl ketone derivatives fom thloamides via episulfides and thloiminium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetonitriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Heptic Agents , Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thienyl)imidazole Derivatives with Antinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8): 3111-3120 (1996).	
		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bioorganic & Medicinal Chemnistry Letters, 6:24 3009-3112 (1996).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).	
		TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).	
		VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitriles, Stud. Univ. Babes-Bolyai, Ser. Chem., 13(2):31-5 (English abstract of article in Romanian) (1968).	
		VARGHESE, The structure and resonance Raman spectra--structure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithioester, Can. J. Chem., 64(8):1668-1673 (1986).	
		YAMADA, et al., Studies of unusual amino acids and their peptides. IX. The synthetic study of bottomycins B1 and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.	
		, Derwent Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		09/927,186		CAI, et al.	08-10-2001	
		09/927,324		BUTLER, et al.	08-10-2001	
		09/928,122		BREITENBUCHER, et al.	08-10-2001	
		09/946,214		GU, et al.	09-05-2001	
		10/042,565		QUIBELL, et al.	11-16-2001	
		10/148,612		OHMOTO, et al.	08-21-2002	
		10/148,613		OHMOTO, et al.	08-28-2002	
		10/181,713		OHMOTO, et al.	07-22-2002	
		10/181,799		OHMOTO, et al.	07-23-2002	
		10/231,425		BUXTON, et al	08-28-2002	
		10/256,512		BEKKALI, et al.	09-27-2002	
		10/258,053		CUMMINGS, et al.	10-17-2002	
		10/275,583		COWEN, et al.	11-07-2002	
		10/279,424		BEKKALI, et al.	10-24-2002	
		10/466,385		QUIBELL, et al.	01-08-2004	
		6,015,791		GYORKOS, et al.	01-18-2000	
		6,608,057		CYWIN, et al.	08-18-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
		JP	JP 2001-011037		SATO, et al.	01-16-2001		
		JP	JP 2001-055366		SATO, et al.	02-27-2001		
		WO	WO00/59881		SINGH, et al.	10-12-2000		
		WO	WO01/09169		SINGH, et al.	02-08-2001		
		WO	WO02/057248		QUIBELL, et al.	07-25-2002		
		WO	WO02/057249		QUIBELL, M	07-25-2002		
		WO	WO02/057270		QUIBELL, M	07-25-2002		
		WO	WO02/096892		OHMOTO, et al.	05-30-2002		
		WO	WO02/100849		HICKEY, et al.	12-19-2002		
		WO	WO02/20485		BEKKALI, et al.	03-14-2002		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		CHAPMAN, et al., Emerging Roles for Cysteine Proteases in Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.	
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-206.	
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202.	
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K., Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.	
		GREENSPAN, et al., Identification of Dipeptidyl Nitriles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Chem.; 2001; 44; pp.4524-4534.	
		LOWE, et al., Kinetic Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.	
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.	
		MARQUIS, et al., Azaanone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(9); pp.1380-1395.	
		NAKAGAWA, et al., Imparied Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	
		OTTO, et al., Cysteine Proteases and their Inhibitors, Chem. Rev.; 1997; 97; pp.133-171.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 13

Complete if Known	
Application Number	10/787,367
Filing Date	02/26/2004
First Named Inventor	GRAUPE
Group Art Unit	1626
Examiner Name	Coppins, Janet
Attorney Docket Number	USAV2001/0143 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastinolytic Cysteine Protease, J. Biol. Chem.; 1992; 267; pp.7258-7262.	
		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517.	
		VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest.; 1998; 101(10); pp.2351-2363.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.